Jan Steyaert receives prestigious Gabbay Award for pioneering work on Nanobody® technology

Steyaert is the first Belgian scientist to receive the prestigious American award for outstanding science with a translational character

Jan Steyaert, director of the VIB-VUB Center for Structural Biology and professor at Vrije Universiteit Brussel (VUB), is the first Belgian scientist to receive the Jacob and Louise Gabbay Award. Steyaert was nominated for the award thanks to his contributions to structural biology through the development of Camelid single-domain antibodies or so-called Nanobodies. The discovery of these small antibodies has led to important breakthroughs in medicine and agriculture, with practical applications already on the market today.

Each year, the Boston based Brandeis University presents the Jacob and Louise Gabbay award to scientists in academia, medicine, or industry whose work has led to outstanding scientific breakthroughs with practical applications. The 24th edition of the award goes to VUB-professor Jan Steyaert for his essential contributions to nanotechnology and the translational characteristics of his research.

Steyaert was instrumental in the development and engineering of Nanobodiesor Camelid single-domain antibodies for applications in structural biology and drug design. This groundbreaking technology is used to study the structure and function of proteins, which significantly advances scientific knowledge. To date, the Nanobody technology sees a broad spectrum of applications, both in medicine and agriculture. The technology was at the basis of three VIB spin-off companies, Ablynx, Biotalys, and ConfoTherapeutics, that use Nanobodies to develop therapeutic interventions for life-threatening diseases and crop protection.

Dagmar Ringe, Chair of the Award Committee: “Jan Steyaert is being recognized for the introduction of nanobody technology as exquisite tools to lock inherently unstable, dynamic proteins into single functional conformations. His work is not only important for mechanisms in structural biology but also structure-based drug discovery within the context of the pharmaceutical industry.”

Nanobody pioneers are far from finished?

The Steyaert lab pioneered the use of nanobodies in X-ray crystallography, aiming at the highest-hanging fruits of structural biology including membrane proteins, amyloidogenic proteins, and now also (transient) multiprotein complexes. More recently, the lab is focusing on exploiting Nanobodies for drug discovery on difficult targets like GPCRs and on the engineering of nanobodies to be used in single-particle cryo-EM and OMICs applications. The key of Steyaert’s success lies in sharing these disruptive technologies with the best research teams in the world and moving past the barriers of protein science and drug discovery.

The Gabbay award is a meaningful recognition of the importance of Steyaert’s discoveries and a welcome reminder of the potential applications of Nanobody technology. Steyaert is the first Belgian scientist to join a list of influential scientists such as Jennifer Doudna and Emmanuelle Charpentier having received the Gabbay Award. The award was presented on October 27th in a ceremony co-sponsored by the Office of the President and the Rosenstiel Basic Medical Sciences Research Center at Brandeis University in Massachusetts.

Jan Steyaert, VIB-VUB Center for Structural Biology: “The technologies we develop are becoming mainstream in Europe. This prestigious award from overseas illustrates our global impact on basic research and on the biotech industry as a whole.”

More info can be found on www.steyaertlab.brussels

Joran Lauwers

Joran Lauwers

Press Contact, VIB

About Jan Steyaert

Jan Steyaert is a Highly Cited Researcher affiliated to Vrije Universiteit Brussel and VIB. His publications are in the top 1% for citations by other researchers. As a successful serial entrepreneur, he and his team are also on the verge to incubate new ventures.

About the VIB-VUB Center for Structural Biology
Proteins are the most important building blocks of all life. They are responsible for the metabolic processes in a cell, they give the cell its shape and enable cooperation between the various cells and tissues in our bodies. Scientists at the VIB-VUB Center for Structural Biology study the basic principles that determine the function and action of a protein in the cell. In this way, we can develop new technologies and bio-based materials.

More info can be found www.structuralbiology.brussels

Share

Latest stories

Website preview
Blocking lipid production in healthy lung cells can reduce lung metastasis
Leuven, 17 March 2026 - Scientists from the VIB–KU Leuven Center for Cancer Biology, in collaboration with the Francis Crick Institute, have discovered how cancer cells can exploit healthy lung cells to support metastatic tumor growth in the lungs. In two complementary studies published in Nature Cell Biology and Cancer Discovery, they show that tumors use lipids produced by lung cells as signals, and that decreasing the lipid production of lung cells can decrease metastasis. The findings point to new therapeutic strategies that target lung cell lipid production, rather than cancer cells themselves, which may also help refine patient selection for ongoing clinical trials targeting this pathway.
press.vib.be
Website preview
Researchers identify major genetic risk factor for rare form of dementia
Antwerp, 12 March 2026 - Researchers at VIB and Antwerp University have identified a major genetic risk factor for a rare form of frontotemporal dementia. The discovery, published today in Nature Genetics, provides a biological entry point for a disease subtype that has been difficult to study. It could not only help to improve diagnosis and patient stratification, but also opens up new avenues toward targeted treatments.
press.vib.be
Website preview
Protealis Announces Regulatory Approval of its First Biological Solution MagNfixTM and Launch of Five New Soybean Varieties
Ghent (Belgium), 11 March 2026 – Protealis, the European specialist in non-GMO legume seeds and seed technologies, today announces several milestones that significantly strengthen its position in a fast-growing European soybean market. The company has obtained European regulatory approval from EFCI1 (EU Fertilising Products Regulation (FPR) 2019/1009) for MagNfix™, its first biological solution, which is a proprietary soybean inoculant seed coating that is designed to support higher soybean yield and protein content. In addition, Protealis has secured the registration of five new soybean varieties across four European countries. This includes the introduction of two new maturity group (MG) 000 soybean varieties in Poland, the registration of its first maturity group 0000 ultra-early soybean variety in France, and a new soy variety registration for Belgium. In Germany, Protealis received registration for its second 00 MG soybean variety suited for the regions in southern Germany...
press.vib.be

About VIB Press

VIB is an independent research institute that translates insights in biology into impactful innovations for society. Collaborating with the five Flemish universities, it conducts research in plant biology, cancer, neuroscience, microbiology, inflammatory diseases, artificial intelligence and more. VIB connects science with entrepreneurship and stimulates the growth of the Flemish biotech ecosystem. The institute contributes to solutions for societal challenges such as new methods for diagnostics and treatments, as well as innovations for agriculture. 

Learn more at www.vib.be.

Contact

Suzanne Tassierstraat 1 9052 Zwijnaarde

+32 9 244 66 11

press@vib.be

vib.be